Tuhura Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for Vista-101 Clinical Trial Evaluating Kva12123 in Patients With Advanced Solid Tumor Cancer
Tuhura Biosciences和kintara therapeutics宣佈Kineta公司重新開放招募參與高級實體瘤癌患者評估kva12123的Vista-101臨床試驗